Drug intelligence / Profile preview

EFRH-phage

Development stage: Preclinical
Modality: Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intranasal, Intraperitoneal, Subcutaneous

Overview

EFRH-phage is an engineered filamentous phage designed to display the EFRH sequence, which is a part of the amyloid-beta peptide. It serves as an antigen carrier to elicit an immune response against amyloid-beta, potentially reducing amyloid burden in the brain and improving cognitive functions in models of Alzheimer's disease[1].

Targets

Amyloid-beta peptide aggregates and fibrils (EFRH epitope)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on EFRH-phage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EFRH-phage.

Explore the full profile